Pay in 4 interest-free payments of $7.36 Learn more
Ships within 48 hours · Estimated delivery Aug 15 - Aug 20
To address the rising costs associated with GLP-1 agonists and obesity treatment, employers should consider a comprehensive strategy
doi:10.4103/0975-1483.80303
Coverage of GLP-1 weight-loss drugs is growing among the largest employers (5000+ workers), now at 43%
Many conventional glucose-lowering therapies require dose adjustment or are contraindicated in severe renal impairment, leaving limited therapeutic options
US$ 21.01
US$ 25.57
US$ 21.08
US$ 23.79
US$ 25.70
US$ 28.90
US$ 28.96
US$ 22.76
US$ 23.93
US$ 29.29
